Cargando…

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old

Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Greish, Khaled, Alawadhi, Abdulla, Jaradat, Ahmed, Almarabheh, Amer, AlMadhi, Marwa, Jawad, Jaleela, Alsaffar, Basma, Alalawi, Ejlal, Alsayyad, Adel, Merza, Afaf, Alalawi, Batool, Qayed, Donia, Humaidan, Ahmed, Al Qahtani, Manaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/
https://www.ncbi.nlm.nih.gov/pubmed/35455335
http://dx.doi.org/10.3390/vaccines10040586
_version_ 1784691535988654080
author Greish, Khaled
Alawadhi, Abdulla
Jaradat, Ahmed
Almarabheh, Amer
AlMadhi, Marwa
Jawad, Jaleela
Alsaffar, Basma
Alalawi, Ejlal
Alsayyad, Adel
Merza, Afaf
Alalawi, Batool
Qayed, Donia
Humaidan, Ahmed
Al Qahtani, Manaf
author_facet Greish, Khaled
Alawadhi, Abdulla
Jaradat, Ahmed
Almarabheh, Amer
AlMadhi, Marwa
Jawad, Jaleela
Alsaffar, Basma
Alalawi, Ejlal
Alsayyad, Adel
Merza, Afaf
Alalawi, Batool
Qayed, Donia
Humaidan, Ahmed
Al Qahtani, Manaf
author_sort Greish, Khaled
collection PubMed
description Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain. Subjects and Methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody. Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9–12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35. Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer.
format Online
Article
Text
id pubmed-9028114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90281142022-04-23 Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old Greish, Khaled Alawadhi, Abdulla Jaradat, Ahmed Almarabheh, Amer AlMadhi, Marwa Jawad, Jaleela Alsaffar, Basma Alalawi, Ejlal Alsayyad, Adel Merza, Afaf Alalawi, Batool Qayed, Donia Humaidan, Ahmed Al Qahtani, Manaf Vaccines (Basel) Article Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain. Subjects and Methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody. Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9–12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35. Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer. MDPI 2022-04-11 /pmc/articles/PMC9028114/ /pubmed/35455335 http://dx.doi.org/10.3390/vaccines10040586 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Greish, Khaled
Alawadhi, Abdulla
Jaradat, Ahmed
Almarabheh, Amer
AlMadhi, Marwa
Jawad, Jaleela
Alsaffar, Basma
Alalawi, Ejlal
Alsayyad, Adel
Merza, Afaf
Alalawi, Batool
Qayed, Donia
Humaidan, Ahmed
Al Qahtani, Manaf
Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title_full Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title_fullStr Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title_full_unstemmed Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title_short Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
title_sort safety and immunogenicity of covid-19 bbibp-corv vaccine in children 3–12 years old
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/
https://www.ncbi.nlm.nih.gov/pubmed/35455335
http://dx.doi.org/10.3390/vaccines10040586
work_keys_str_mv AT greishkhaled safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alawadhiabdulla safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT jaradatahmed safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT almarabhehamer safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT almadhimarwa safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT jawadjaleela safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alsaffarbasma safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alalawiejlal safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alsayyadadel safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT merzaafaf safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alalawibatool safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT qayeddonia safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT humaidanahmed safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold
AT alqahtanimanaf safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold